Clinical Trials Logo
  1. Home
  2. Renal Transplant Recipients
  3. NCT00138970

Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk

Renal Transplant Recipients Clinical Trial

Official title:
Randomised, Double-Arm, Controlled, Open-Label Study Comparing Calcineurin Inhibitor-Free Immunosuppression (Zenapax®, CellCept® and Prednisolone) and Cyclosporine A Based Immunosuppression (Sandimmun Neoral®, CellCept® and Prednisolone) on the Outcome of Renal Function and Acute Rejection in 0 DR Mis-Matched Renal Allograft Recipients

Clinical Trial Summary

To compare renal function (51Cr-EDTA clearance) 12 months posttransplant, in primary renal allograft recipients (from cadaveric donor) at low immunogenic risk, 0 DR mis-match, receiving immunosuppressive therapy with A) Zenapax® (5 doses), CellCept® (1.5 g bid., aiming for TDM for total trough concentrations of 2-6 mg/L) and prednisolone or B) Sandimmun Neoral® (full dose), CellCept® (1.0 g bid.) and prednisolone.

Clinical Trial Description

Primary Objective To compare renal function (51Cr-EDTA clearance) 12 months posttransplant, in primary renal allograft recipients (from cadaveric donor) at low immunogenic risk, 0 DR mis-match, receiving immunosuppressive therapy with A) Zenapax® (5 doses), CellCept® (1.5 g bid., aiming for TDM for total trough concentrations of 2-6 mg/L) and prednisolone or B) Sandimmun Neoral® (full dose), CellCept® (1.0 g bid.) and prednisolone.

Secondary Objectives To compare the two treatment groups with regard to: patient and graft survival (12 months), biopsy-proven and presumptive rejection episodes (3 and 12 months), posttransplant (12 months) incidence and severity of hypertension, hyperlipidemia, glucose intolerance, incidence of infection and tolerability and “success rate” of TDM guided CellCept® dosing in a calcineurin inhibitor-free immunosuppressive protocol over 12 months. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00138970
Study type Interventional
Source University of Oslo School of Pharmacy
Contact
Status Completed
Phase Phase 4
Start date January 2002
Completion date February 2005
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02956005 - Envarsus XR in African American Renal Transplant Recipients N/A
Completed NCT01086904 - Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients Phase 2
Completed NCT00319189 - Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients Phase 4
Completed NCT01859832 - Validation of a Novel Diagnostic Tool for the Evaluation of Post Renal Transplant Immunosuppression: The ImmuKnow Assay N/A
Recruiting NCT03110406 - Effects of Whole-body Vibration Training on the Heart Rate Variability Cardiac in Kidney Transplantation N/A
Recruiting NCT02973464 - The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population Phase 3
Active, not recruiting NCT03797196 - RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients Phase 4
Terminated NCT01318915 - Research Study of ATG and Rituximab in Renal Transplantation Early Phase 1
Recruiting NCT00327483 - Web Based Renal Transplant Patient Medication Education Phase 4
Terminated NCT00271830 - Sexual Function in Male Renal Transplant Patients N/A
Withdrawn NCT04903054 - Selective CD28 Blockade in Renal Transplant Recipients Phase 2
Completed NCT02706678 - Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients Phase 4
Active, not recruiting NCT04218721 - Implementing eHealth Interventions Into Regular Clinical Practice N/A
Recruiting NCT03726307 - Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study Phase 1